
Journal ‚pharmazeutische medizin’ • 1/2018
ZUR SACHE
European Medicines Agency: From Business as it used to be to New Horizons
PRO & CONTRA
Paediatric Investigation Plans (PIPs): Chance oder Nachteil – eine Entgegnung
CONSILIUM
AMNOG meets EMA—Methodological Areas of Debate from an Industry Point of View
KONTAKT | IMPRESSUM | DATENSCHUTZERKLÄRUNG © Copyright 2020 DGPharMed